American Century Companies Inc. Acquires Shares of 76,460 XBiotech Inc. (NASDAQ:XBIT)

American Century Companies Inc. purchased a new position in shares of XBiotech Inc. (NASDAQ:XBIT - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 76,460 shares of the biopharmaceutical company's stock, valued at approximately $393,000. American Century Companies Inc. owned 0.25% of XBiotech as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of XBIT. Empowered Funds LLC boosted its position in shares of XBiotech by 7.9% during the first quarter. Empowered Funds LLC now owns 64,277 shares of the biopharmaceutical company's stock worth $523,000 after buying an additional 4,725 shares during the period. Vanguard Group Inc. boosted its holdings in XBiotech by 1.6% in the first quarter. Vanguard Group Inc. now owns 895,315 shares of the biopharmaceutical company's stock valued at $7,279,000 after purchasing an additional 13,804 shares during the period. Bank of New York Mellon Corp boosted its holdings in XBiotech by 102.9% in the second quarter. Bank of New York Mellon Corp now owns 98,314 shares of the biopharmaceutical company's stock valued at $505,000 after purchasing an additional 49,863 shares during the period. Finally, Rhumbline Advisers boosted its holdings in XBiotech by 2,568.5% in the second quarter. Rhumbline Advisers now owns 20,094 shares of the biopharmaceutical company's stock valued at $103,000 after purchasing an additional 19,341 shares during the period. 55.70% of the stock is currently owned by hedge funds and other institutional investors.

XBiotech Trading Up 6.1 %

NASDAQ:XBIT traded up $0.43 during midday trading on Friday, reaching $7.48. The company had a trading volume of 19,285 shares, compared to its average volume of 83,159. The firm has a market capitalization of $227.84 million, a price-to-earnings ratio of -7.03 and a beta of 1.41. The stock's fifty day simple moving average is $6.74 and its 200-day simple moving average is $7.15. XBiotech Inc. has a 12-month low of $3.51 and a 12-month high of $9.96.

XBiotech (NASDAQ:XBIT - Get Free Report) last released its earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter.

XBiotech Company Profile

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.